XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 15 - Phaseone Divestiture

9 Months Ended

Sep. 30, 2025

Wound Care [Member]

Notes to Financial Statements

Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

NOTE 15. PHASEONE DIVESTITURE

On January 3, 2025, the Company entered into a Trademark Acquisition Agreement with its distributor, PhaseOne Health LLC (“PhaseOne”), that provided for the purchase by PhaseOne of two of the Company’s wound care trademarks (the “Wound Care Trademarks”) for a purchase price of $500,000 (the “Trademark Acquisition Agreement,” and such sale, the “PhaseOne Divestiture”). In connection with the PhaseOne Divestiture, the Company also entered into a Transition Services Agreement, dated January 3, 2025, with PhaseOne (the “PhaseOne Transition Services Agreement”), pursuant to which the Company: (i) provided limited transition services to PhaseOne until January 10, 2025; (ii) sold the Company’s existing PhaseOne finished goods inventory from an outstanding purchase order to PhaseOne for an aggregate payment of $126,000; and (iii) a limited amount of remaining componentry inventory. In addition, the PhaseOne Transition Services Agreement provided that the existing supplier and distributor relationship between the Company and PhaseOne would be terminated upon the closing of the PhaseOne Divestiture. The Company completed the PhaseOne Divestiture on January 8, 2025. The Company recorded a net gain of $0.5 million as a result of the PhaseOne Divestiture during the quarter ended March 31, 2025.

The accounting requirements for reporting results related to the Wound Care Trademarks as discontinued operations were met during the first quarter of 2025. Accordingly, the unaudited condensed consolidated financial statements and notes to the unaudited condensed consolidated financial statements reflect the results related to the Wound Care Trademarks as a discontinued operation for the years presented.

In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of discontinued operations in the condensed consolidated balance sheets. The assets and liabilities related to the Wound Care Trademarks have been reflected as discontinued operations in the condensed consolidated balance sheets as of December 31, 2024, and consist of the following (in thousands):

		Balance at December 31, 2024
ASSETS
Current assets:
Accounts receivable, net		$	6
Inventory, net			48
Total current assets, discontinued operations		$	54

LIABILITIES
Liabilities:
Current liabilities:
Accounts payable		$	43
Total current liabilities, discontinued operations		$	43

In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the condensed consolidated statements of operations. Results related to the Wound Care Trademarks for the three and nine months ended September 30, 2025 and 2024 have been reflected as discontinued operations in the condensed consolidated statements of operations and consist of the following (in thousands):

		Three Months Ended September 30,								Nine Months Ended September 30,
		2025				2024				2025				2024

Net sales		$	—			$	5			$	122			$	252
Cost of goods sold			—				62				75				144
Gross profit			—				(57	)			47				108
Operating expenses:
Research and development			—				4				3				32
Total operating expenses			—				4				3				32
Operating (loss) income			—				(61	)			44				76
Gain on divestiture			—				—				500				—
Net (loss) income from discontinued operations before income taxes			—				(61	)			544				76
(Benefit) Provision for income taxes			(2	)			—				10				—

Net income (loss) from discontinued operations, net of taxes		$	2			$	(61	)		$	534			$	76

In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the condensed consolidated statements of cash flows. Results related to the Wound Care Trademarks for the nine months ended September 30, 2025 and 2024 have been reflected as discontinued operations in the condensed consolidated statements of cash flows and consist of the following (in thousands):

		Nine Months Ended September 30,
		2025				2024

Operating activities:
Net income from discontinued operations		$	534			$	76
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash gain on divestiture			(500	)			—
Changes in operating assets and liabilities:
Accounts receivable			6				6
Inventory			43				49
Prepaid expenses and other current assets			—				—
Accounts payable and accrued liabilities			(38	)			(65	)
Net cash provided by operating activities, discontinued operations			45				66

Investing activities:
Proceeds from divestiture			500				—
Net cash provided by investing activities, discontinued operations			500				—

Net increase in cash and cash equivalents, discontinued operations		$	545			$	66